|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wentzensen N, Clarke MA, Bremer R, Poitras
N, Tokugawa D, Goldhoff PE, Castle PE, Schiffman M, Kingery JD,
Grewal KK, et al: Clinical evaluation of human papillomavirus
screening with p16/Ki-67 dual stain triage in a large organized
cervical cancer screening program. JAMA Intern Med. 179:881–888.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen PA, Jhingran A, Oaknin A and Denny
L: Cervical cancer. Lancet. 393:169–182. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arun G, Diermeier SD and Spector DL:
Therapeutic targeting of long non-coding RNAs in cancer. Trends Mol
Med. 24:257–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang CJ, Zhu CC, Xu J, Wang M, Zhao WY,
Liu Q, Zhao G and Zhang ZZ: The lncRNA UCA1 promotes proliferation,
migration, immune escape and inhibits apoptosis in gastric cancer
by sponging anti-tumor miRNAs. Mol Cancer. 18:1152019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qin G, Tu X, Li H, Cao P, Chen X, Song J,
Han H, Li Y, Guo B, Yang L, et al: lncRNA PSTAR promotes p53
signaling by inhibiting hnRNP K deSUMOylation and suppresses
hepatocellular carcinoma. Hepatology. 2019.
|
|
8
|
Bartonicek N, Maag JL and Dinger ME: Long
noncoding RNAs in cancer: Mechanisms of action and technological
advancements. Mol Cancer. 15:432016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim HJ, Lee DW, Yim GW, Nam EJ, Kim S, Kim
SW and Kim YT: Long non-coding RNA HOTAIR is associated with human
cervical cancer progression. Int J Oncol. 46:521–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang L, Liao LM, Liu AW, Wu JB, Cheng XL,
Lin JX and Zheng M: Overexpression of long noncoding RNA HOTAIR
predicts a poor prognosis in patients with cervical cancer. Arch
Gynecol Obstet. 290:717–723. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo W, Wang M, Liu J, Cui X and Wang H:
Identification of a six lncRNAs signature as novel diagnostic
biomarkers for cervical cancer. J Cell Physiol. 235:993–1000. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Agostino S, Valenti F, Sacconi A,
Fontemaggi G, Pallocca M, Pulito C, Ganci F, Muti P, Strano S and
Blandino G: Long non-coding MIR205HG depletes Hsa-miR-590-3p
leading to unrestrained proliferation in head and neck squamous
cell carcinoma. Theranostics. 8:1850–1868. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Profumo V, Forte B, Percio S, Rotundo F,
Doldi V, Ferrari E, Fenderico N, Dugo M, Romagnoli D, Benelli M, et
al: LEADeR role of miR-205 host gene as long noncoding RNA in
prostate basal cell differentiation. Nat Commun. 10:3072019.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Percio S, Rotundo F and Gandellini P: Gene
expression dataset of prostate cells upon MIR205HG/LEADR
modulation. Data Brief. 29:1051392020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gong W, Yang L, Wang Y, Xian J, Qiu F, Liu
L, Lin M, Feng Y, Zhou Y and Lu J: Analysis of survival-related
lncRNA landscape identifies a role for LINC01537 in energy
metabolism and lung cancer progression. Int J Mol Sci. 20:37132019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Zhu X, Dong P and Cai J: Long
noncoding RNA LINC00958 promotes the oral squamous cell carcinoma
by sponging miR-185-5p/YWHAZ. Life Sci. 242:1167822019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao H, Zheng GH, Li GC, Xin L, Wang YS,
Chen Y and Zheng XM: Long noncoding RNA LINC00958 regulates cell
sensitivity to radiotherapy through RRM2 by binding to
microRNA-5095 in cervical cancer. J Cell Physiol. 234:23349–23359.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu Y, Feng C, Liu T, Zhang B and Yang L:
The downregulation of lncRNA EMX2OS might independently predict
shorter recurrence-free survival of classical papillary thyroid
cancer. PLoS One. 13:e02093382018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gulìa C, Baldassarra S, Signore F, Rigon
G, Pizzuti V, Gaffi M, Briganti V, Porrello A and Piergentili R:
Role of non-coding RNAs in the etiology of bladder cancer. Genes
(Basel). 8:3392017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Romagosa C, Simonetti S, López-Vicente L,
Mazo A, Lleonart ME, Castellvi J and Cajal SR: p16(Ink4a)
overexpression in cancer: A tumor suppressor gene associated with
senescence and high-grade tumors. Oncogene. 30:2087–2097. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Wang H and Huang H: Long non-coding
RNA MIR205HG function as a ceRNA to accelerate tumor growth and
progression via sponging miR-122-5p in cervical cancer. Biochem
Biophys Res Commun. 514:78–85. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inglis-Broadgate SL, Thomson RE, Pellicano
F, Tartaglia MA, Pontikis CC, Cooper JD and Iwata T: FGFR3
regulates brain size by controlling progenitor cell proliferation
and apoptosis during embryonic development. Dev Biol. 279:73–85.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kandimalla R, Masius R, Beukers W, Bangma
CH, Orntoft TF, Dyrskjot L, van Leeuwen N, Lingsma H, van Tilborg
AAG and Zwarthoff EC: A 3-plex methylation assay combined with the
FGFR3 mutation assay sensitively detects recurrent bladder cancer
in voided urine. Clin Cancer Res. 19:4760–4769. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Javidi-Sharifi N, Traer E, Martinez J,
Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP,
Druker BJ and Tyner JW: Crosstalk between KIT and FGFR3 promotes
gastrointestinal stromal tumor cell growth and drug resistance.
Cancer Res. 75:880–891. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pouessel D, Neuzillet Y, Mertens LS, van
der Heijden MS, de Jong J, Sanders J, Peters D, Leroy K, Manceau A,
Maille P, et al: Tumor heterogeneity of fibroblast growth factor
receptor 3 (FGFR3) mutations in invasive bladder cancer:
Implications for perioperative anti-FGFR3 treatment. Ann Oncol.
27:1311–1316. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He F, Melamed J, Tang MS, Huang C and Wu
XR: Oncogenic HRAS activates epithelial-to-mesenchymal transition
and confers stemness to p53-deficient urothelial cells to drive
muscle invasion of basal subtype carcinomas. Cancer Res.
75:2017–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Murugan AK, Grieco M and Tsuchida N: RAS
mutations in human cancers: Roles in precision medicine. Semin
Cancer Biol. 59:23–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
